Florian Roghmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7323873/publications.pdf

Version: 2024-02-01

81 1,918 23 41 papers citations h-index g-index

82 82 82 82 2967

82 82 82 2967 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 63.e9-63.e18.	0.8	5
2	Psychosocial Distress in the Early Recovery Period after Radical Prostatectomy. Urologia Internationalis, 2022, 106, 891-896.	0.6	2
3	A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. European Urology Oncology, 2022, , .	2.6	10
4	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. European Journal of Cancer, 2022, 167, 13-22.	1.3	15
5	Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatmentâ€"A Retrospective Multicenter Analysis. Cancers, 2022, 14, 2850.	1.7	3
6	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World Journal of Urology, 2021, 39, 443-451.	1.2	13
7	Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. World Journal of Urology, 2021, 39, 11-25.	1.2	23
8	Probability of Prostate Cancer Diagnosis following Negative Systematic and Targeted MRI: Transrectal Ultrasound Fusion Biopsy: A Real-Life Observational Study. Urologia Internationalis, 2021, 105, 446-452.	0.6	0
9	KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 473.	1.1	5
10	Identification of patients at risk for biochemical recurrence after radical prostatectomy with intraâ€operative frozen section. BJU International, 2021, 128, 598-606.	1.3	0
11	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 413-418.	0.6	8
12	Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different softwareâ€based systems. Prostate, 2021, , .	1.2	5
13	How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer. Urologia Internationalis, 2021, , 1-6.	0.6	0
14	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. European Urology Focus, 2020, 6, 1226-1232.	1.6	18
15	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
16	Changing the Prostate Cancer Detection Paradigm: Clinical Application of European Association of Urology Guideline–recommended Magnetic Resonance Imaging–based Risk Stratification in Men with Suspected Prostate Cancer. European Urology Focus, 2020, 7, 1011-1018.	1.6	3
17	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. Surgical Oncology. 2020. 34. 312-317.	0.8	7
18	In-Vitro Identification and In-Vivo Confirmation of DNA Methylation Biomarkers for Urothelial Cancer. Biomedicines, 2020, 8, 233.	1.4	1

#	Article	IF	CITATIONS
19	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 851.e19-851.e25.	0.8	6
20	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. European Urology Open Science, 2020, 22, 45-50.	0.2	6
21	Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial*. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 886-895.	0.8	22
22	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e651-e659.	0.9	7
23	Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data Journal of Clinical Oncology, 2020, 38, 493-493.	0.8	2
24	Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer Journal of Clinical Oncology, 2020, 38, 562-562.	0.8	0
25	Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer Journal of Clinical Oncology, 2020, 38, 530-530.	0.8	0
26	Editorial: early PSA-testing after radical prostatectomyâ€"the truth behind the scenes. Translational Andrology and Urology, 2019, 8, S307-S309.	0.6	0
27	Transurethral resection of bladder tumours: established and new methods of tumour visualisation. Translational Andrology and Urology, 2019, 8, 25-33.	0.6	6
28	Salvage lymph node dissection in hormone-na \tilde{A} -ve men: How effective is surgery?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 812.e17-812.e24.	0.8	6
29	TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration. International Journal of Molecular Sciences, 2019, 20, 4483.	1.8	14
30	Parastomal Hernia Repair With 3-D Mesh Implants After Radical Cystectomy and Ileal Conduit Urinary Diversion - A Single-center Experience Using a Purpose Made Alloplastic Mesh Implant. Urology, 2019, 131, 245-249.	0.5	9
31	The need to improve TURB: a diagnostic and therapeutic fundamental first step in the disease's management. Translational Andrology and Urology, 2019, 8, 2-4.	0.6	4
32	The present and future of non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 1-1.	0.6	1
33	Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer. American Journal of Pathology, 2019, 189, 619-631.	1.9	39
34	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey. European Urology Focus, 2019, 5, 681-688.	1.6	48
35	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus, 2019, 5, 242-249.	1.6	11
36	Interdisciplinary Comparison of PADUA and R.E.N.A.L. Scoring Systems for Prediction of Conversion to Nephrectomy in Patients with Renal Mass Scheduled for Nephron Sparing Surgery. Journal of Urology, 2019, 202, 890-898.	0.2	16

#	Article	IF	CITATIONS
37	The value of nephrometry scoring systems in prediction of conversion to radical nephrectomy in patients scheduled for nephron-sparing surgery. Annals of Translational Medicine, 2019, 7, 704-704.	0.7	O
38	Reply by Authors. Journal of Urology, 2019, 202, 897-898.	0.2	0
39	Conditional analyses of recurrence and progression in patients with TaG1 non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e19-238.e27.	0.8	3
40	De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer. Neurourology and Urodynamics, 2018, 37, 1988-1995.	0.8	4
41	Factors Influencing Prostate Specific Antigen Testing in the United States. Urology Practice, 2018, 5, 438-443.	0.2	1
42	Integrating spatial, morphological, and textural information for improved cell type differentiation using Raman microscopy. Journal of Chemometrics, 2018, 32, e2973.	0.7	9
43	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node–Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	1.6	18
44	Periâ€operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity scoreâ€weighted European multicentre study. BJU International, 2018, 121, 101-110.	1.3	21
45	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e13-78.e19.	0.8	16
46	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World Journal of Urology, 2017, 35, 1401-1407.	1.2	29
47	Noninvasive Diagnosis of High-Grade Urothelial Carcinoma in Urine by Raman Spectral Imaging. Analytical Chemistry, 2017, 89, 6893-6899.	3.2	38
48	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	0.9	21
49	Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prevention Research, 2017, 10, 588-597.	0.7	46
50	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. European Journal of Surgical Oncology, 2017, 43, 2193-2199.	0.5	9
51	Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. Acta Neuropathologica Communications, 2017, 5, 40.	2.4	13
52	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clinical Genitourinary Cancer, 2017, 15, 356-362.	0.9	31
53	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. Translational Andrology and Urology, 2017, 6, 1067-1080.	0.6	19
54	Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas. Oncotarget, 2017, 8, 104946-104959.	0.8	7

#	Article	IF	CITATIONS
55	Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 432.e1-432.e8.	0.8	8
56	Prediction of cancerâ€specific survival after radical cystectomy in <scp>pT4a</scp> urothelial carcinoma of the bladder: development of a tool for clinical decisionâ€making. BJU International, 2016, 117, 272-279.	1.3	29
57	Open Versus Robotic Radical Prostatectomy in Obese Men. Current Urology, 2015, 8, 156-161.	0.4	12
58	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. European Urology Focus, 2015, 1, 75-81.	1.6	6
59	Impact of Real-Time Elastography on Magnetic Resonance Imaging/Ultrasound Fusion Guided Biopsy in Patients with Prior Negative Prostate Biopsies. Journal of Urology, 2015, 193, 1191-1197.	0.2	39
60	Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World Journal of Urology, 2015, 33, 1753-1761.	1.2	28
61	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World Journal of Urology, 2015, 33, 2107-2113.	1.2	16
62	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. World Journal of Urology, 2015, 33, 1945-1950.	1.2	28
63	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 17.e9-17.e18.	0.8	24
64	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. Canadian Urological Association Journal, 2015, 9, 207.	0.3	13
65	Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study. Canadian Urological Association Journal, 2014, 8, 419.	0.3	4
66	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Canadian Urological Association Journal, 2014, 8, 148.	0.3	42
67	Emergency Department Visits in the United States for Upper Urinary Tract Stones: Trends in Hospitalization and Charges. Journal of Urology, 2014, 191, 90-96.	0.2	88
68	Local tumor destruction in renal cell carcinomaâ€"An inpatient population-based study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 54.e1-54.e7.	0.8	10
69	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. European Urology, 2014, 66, 913-919.	0.9	103
70	Standardized assessment of complications in a contemporary series of <scp>E</scp> uropean patients undergoing radical cystectomy. International Journal of Urology, 2014, 21, 143-149.	0.5	106
71	Mental health outcomes in elderly men with prostate cancer1Equal contribution Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	0.8	59
72	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. Journal of Urology, 2014, 191, 1678-1684.	0.2	19

#	Article	lF	CITATIONS
73	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. European Urology, 2014, 66, 361-370.	0.9	125
74	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	0.9	156
75	Reply to Vladimir Novotny, Manfred P. Wirth, Michael Froehner's Letter to the Editor re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. Eur Urol 2014:66:156–163. European Urology. 2014. 66. e14.	0.9	1
76	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	0.8	25
77	Incidence of Priapism in Emergency Departments in the United States. Journal of Urology, 2013, 190, 1275-1280.	0.2	75
78	Incidence and Treatment Patterns in Males Presenting with Lower Urinary Tract Symptoms to the Emergency Department in the United States. Journal of Urology, 2013, 190, 1798-1804.	0.2	15
79	Intraoperative Frozen Section of the Prostate Decreases Positive Margin Rate While Ensuring Nerve Sparing Procedure During Radical Prostatectomy. Journal of Urology, 2013, 190, 515-520.	0.2	46
80	Updated assessment of neoblader utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. Canadian Urological Association Journal, 2013, 7, 552.	0.3	34
81	Is there a need for the Fournier's gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier's gangrene. BJU International, 2012, 110, 1359-1365.	1.3	69